English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  51496431    線上人數 :  728
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"jia horng kao"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 581-605 / 1180 (共48頁)
<< < 19 20 21 22 23 24 25 26 27 28 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
臺大學術典藏 2021-09-04T05:17:03Z Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B Tseng C.-H.; Hsu Y.-C.; Chang C.-Y.; Tseng T.-C.; Wu M.-S.; Lin J.-T.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:17:03Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:17:01Z Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection Reau N.; Kwo P.Y.; Rhee S.; Brown R.S.; Jr.; Agarwal K.; Angus P.; Gane E.; JIA-HORNG KAO; Mantry P.S.; Mutimer D.; Reddy K.R.; Tran T.T.; Hu Y.B.; Gulati A.; Krishnan P.; Dumas E.O.; Porcalla A.; Shulman N.S.; Liu W.; Samanta S.; Trinh R.; Forns X.
臺大學術典藏 2021-09-04T05:17:01Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:17:01Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:17:00Z Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study Liu C.-H.; Huang Y.-J.; Yang S.-S.; Chang C.-H.; Yang S.-S.; Sun H.-Y.; Liu C.-J.; Liu W.-C.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:17:00Z Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection Younossi Z.M.; Stepanova M.; Henry L.; Han K.-H.; Ahn S.H.; Lim Y.-S.; Chuang W.-L.; JIA-HORNG KAO; Nguyen K.V.; Lai C.L.; Chan H.L.-Y.; Wei L.
臺大學術典藏 2021-09-04T05:17:00Z One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis Nien H.-C.; Sheu J.-C.; Chi Y.-C.; Chen C.-L.; JIA-HORNG KAO; Yang W.-S.
臺大學術典藏 2021-09-04T05:16:59Z Serine/threonine protein phosphatase 5 is a potential therapeutic target in cholangiocarcinoma Hu M.-H.; Huang T.-T.; Chao T.-I.; Chen L.-J.; Chen Y.-L.; Tsai M.-H.; Liu C.-Y.; JIA-HORNG KAO; Chen K.-F.
臺大學術典藏 2021-09-04T05:16:59Z Highlights JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:59Z Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan Liu C.-H.; Yu M.-L.; Peng C.-Y.; Hsieh T.-Y.; Huang Y.-H.; Su W.-W.; Cheng P.-N.; Lin C.-L.; Lo C.-C.; Chen C.-Y.; Chen J.-J.; Ma Q.; Brooks-Rooney C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:58Z A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment Liu Y.-T.; Tseng T.-C.; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO; Huang L.-R.
臺大學術典藏 2021-09-04T05:16:58Z Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan Liu C.-H.; Liu C.-J.; Su T.-H.; Yang H.-C.; Hong C.-M.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:58Z Sarcopenia and chronic liver diseases Hsu C.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:57Z Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus Yang H.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:57Z Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors’ reply Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:57Z Taiwan consensus statement on the management of chronic hepatitis B Chien R.-N.; JIA-HORNG KAO; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F.
臺大學術典藏 2021-09-04T05:16:56Z Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B Wei L.; Pavlovic V.; Bansal A.T.; Chen X.; Foster G.R.; He H.; JIA-HORNG KAO; Lampertico P.; Liaw Y.-F.; Motoc A.; Papatheodoridis G.V.; Piratvisuth T.; Plesniak R.; Wat C.
臺大學術典藏 2021-09-04T05:16:56Z Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: A systematic review and meta-analysis of individual participant data Pavlovic V.; Yang L.; Chan H.L.-Y.; Hou J.; Janssen H.L.; JIA-HORNG KAO; Lampertico P.; Peng C.-Y.; Piratvisuth T.; Thompson A.J.; Wedemeyer H.; Wei L.; Wat C.
臺大學術典藏 2021-09-04T05:16:56Z Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma Liao S.-H.; Su T.-H.; Jeng Y.-M.; Liang P.-C.; Chen D.-S.; Chen C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:56Z Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction? Liu C.-H.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:55Z Large and middle hepatitis B surface antigen: The lower the better? Lin H.-H.; Tseng T.-C.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:55Z Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; Liu C.-J.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S.
臺大學術典藏 2021-09-04T05:16:55Z Profile and value of FIB-4 in patients with dual chronic hepatitis C and B Liu C.-J.; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; JIA-HORNG KAO
臺大學術典藏 2021-09-04T05:16:54Z Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection Su T.-H.; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; JIA-HORNG KAO

顯示項目 581-605 / 1180 (共48頁)
<< < 19 20 21 22 23 24 25 26 27 28 > >>
每頁顯示[10|25|50]項目